yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q46715452-E1549595-F334-460E-A848-7C7A2BD104BE
Q46715452-E1549595-F334-460E-A848-7C7A2BD104BE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q46715452-E1549595-F334-460E-A848-7C7A2BD104BE
RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.
P2860
Q46715452-E1549595-F334-460E-A848-7C7A2BD104BE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q46715452-E1549595-F334-460E-A848-7C7A2BD104BE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5a4f662b187b21dbc4b95fefb37e9ea7e66e233c
P2860
Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.